Harry Zhabilov and Immunotech Laboratories SEC ISSUES Harry Zhabilov was CEO of IMMB when it was halted
Immunotech Laboratories, Inc. is committed to creating drugs for the better health of mankind.
We strive to become a leader in immuno-therapeutic treatment and prevention of HIV/AIDS, Cancer and other immuno related disorders.
Immunotech Laboratories, Inc. offers the innovative drug platform called IPF, a technology that can be used to facilitate a broad range of applications. Our flagship compound ITV-1, which studies have shown is effective in the treatment of HIV/AIDS and Hepatitis C viruses and to modulate the immune system.